Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Panel Passes Infectious-Disease Fighting Fund

This article was originally published in The Gray Sheet

Executive Summary

The House Appropriations Committee's Labor/HHS Subcommittee approved an additional $300m in funding next year for an "Infectious Disease Rapid Response Reserve Fund" to be run by the Centers for Disease Control and Prevention.

You may also be interested in...

Feds Closer To Dx Distinguishing Zika From Dengue As HHS Tries To Plug Funding Gap

The US Department of Health and Human Services gave up on getting new funding from Congress in 2016 to fight Zika virus, and instead juggled its budget this week to throw $81m at the Zika vaccine effort. And while there has been headway on a test to differentiate Zika from Dengue, HHS Secretary Burwell told House Minority Leader Nancy Pelosi in an Aug. 11 letter that NIH currently lacks funds to support diagnostics and other Zika priorities.

NIH Highlights Advanced Imaging, Neurostim Technologies In Funding Appeal

Further development of medical technologies to advance brain disease diagnoses, treat spinal cord injuries and manage pain without the use of addictive opioids would be key beneficiaries if additional funding from Congress for the National Institutes of Health comes through, NIH head Francis Collins told appropriators.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts